Sanofi reported third-quarter earnings and sales that beat analysts' expectations, boosted by earlier-than-anticipated deliveries of flu and respiratory syncytial virus vaccines and growing demand for ...

Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy ...

Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales of Beyfortus, its ...

French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, boosted ...

French drug major Sanofi (SNYNF, SNY) reported third quarter net income attributable to equity holders of the company of 2.82 billion ...

(Goldman, 10/24) Bloomberg: How Sanofi's Sale Of Consumer Pharma Arm Opella Turned Into A Brawl After a year-long takeover battle for the owner of France’s best-selling painkiller, Sanofi’s decision ...

CD&R this week entered exclusive talks with drugmaker Sanofi to buy half of its consumer arm, Opella. Getting burned on ...

French Economy, Finance and Industry Minister Antoine Armand attends a joint press conference on the government's role ...

Sanofi’s decision to sell its over-the-counter business to a US buyout firm descended into mudslinging, public rebukes and ...

SALES FORECAST: The Paris-based group's sales are forecast at 12.63 billion euros, according to Visible Alpha. That compares with 11.96 billion euros for the same period the year before. As of ...

(Sebastian Guth, 10/16) Emmanuel Macron’s administration has agreed to take a 1%-2% stake in Sanofi SA’s consumer-health unit Opella to sugar the pill of a US private equity takeover, seen as a ...

Leerink Partners analyst David Risinger has maintained their bullish stance on SNYNF stock, giving a Buy rating yesterday. David Risinger has ...